Altered extracellular matrix (ECM) deposition contributing to airway wall remodeling is an
important feature of asthma and chronic obstructive pulmonary disease (COPD). The …

Background QVA149 is an inhaled fixed-dose combination therapy under development for
the treatment of chronic obstructive pulmonary disease (COPD). It combines indacaterol (a …

NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA)
in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium …

Asthma and chronic obstructive pulmonary disease remain a global health problem, with
increasing morbidity and mortality. Despite differences in the causal agents, both diseases …

We evaluated the effect of QVA149, a dual bronchodilator combining indacaterol and
glycopyrronium, on direct patient-reported dyspnoea in patients with moderate-to-severe chronic …

Remodeling of airways and blood vessels is an important feature in chronic obstructive
pulmonary disease (COPD). By using immunohistochemical analysis, we examined bronchial …

Existing evidence indicates that resveratrol, a red wine and grape-derived polyphenolic
antioxidant, can pharmacologically precondition the heart in a nitric oxide (NO)-dependent …

Rationale: Moderate and severe exacerbations are incompletely prevented by maximal
inhalation therapy in patients with severe chronic obstructive pulmonary disease. Objectives: To …

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease
associated with progressive airflow obstruction. Tobacco smoking is the main risk factor …

Background QVA149 is an inhaled, once-daily fixed-dose dual bronchodilator combination
of the long-acting β 2 -agonist indacaterol and long-acting muscarinic antagonist …